DNTH
Dianthus Therapeutics, Inc.
Stock
$88.21−0.11 (−0.12%)Close Oct 2, 2026
Income statement
| Line | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | $0 | $0 | $0 | $0 |
| R&D | $146M | $83M | $33M | $59M | $41M | $28M | $5.8M |
| Operating income | −$178M | −$102M | −$48M | −$83M | −$60M | −$36M | −$9.3M |
| Net income | −$162M | −$85M | −$44M | −$77M | −$58M | −$35M | −$9.4M |
| Diluted EPS | −$4.20 | −$2.55 | −$8.45 | −$2.07 | −$3.13 | −$19.12 | −$65.15 |
| Diluted shares | 38.6M | 33.3M | 5.2M | 37.0M | 18.4M | 1.9M | 149K |
| Revenue growth | −67.3% | +120.6% | — | — | — | — | — |
| Operating margin | −8,739.3% | −1,633.7% | −1,704.7% | — | — | — | — |
| Net margin | −7,973.3% | −1,362.8% | −1,541.2% | — | — | — | — |